Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.05
(
-1.01%
)
Bitcoin
77,596.31
(
1.66%
)
News Focus
News Focus
Post# of 822353
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4173
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: Reefrad post# 560456

Wednesday, 01/18/2023 8:44:34 PM

Wednesday, January 18, 2023 8:44:34 PM

Post# of 822353
But yet, ten well-qualified neuro-oncologists challenged the validity of the NWBO P3 trial. Not often that multiple articles/comments are posted questioning the validity of the trial conclusions. Are both now part of the searchable history of the NWBO publication history so any clinician can read the challenges when they search this study.
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News